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Summary 
The discriminative effects of cyclorphan were studied in pigeons 
trained to discriminate 0.32 mg/kg ethylketazoclne, 1.8 mg/kg 
cyclazocine, or 32 mg/kg naltrexone from saline. A fourth group 
of pigeons was administered i00 mg/kg/day morphine and trained to 
discriminate 0.i mg/kg naltrexone from saline. Cyclorphan produced 
dose-related ethylketazocine-appropriate responding that reached a 
maximum of 83% of the total session responses at 0.3 mg/kg. Higher 
cyclorphan doses produced less ethylketazocine-appropriate respond- 
ing. In pigeons trained to discriminate cyclazocine from saline, 
maximum drug-appropriate responding of greater than 90% occurred at 
5.6-10.0 mg/kg cyclorphan. In narcotic-naive pigeons trained to 
discriminate 32 mg/kg naltrexone from saline, cyclorphan produced a 
maximum of less than 50% drug-appropriate responding. In contrast, 
in pigeons chronically administered morphine and trained to dis- 
criminate 0.I mg/kg naltrexone from saline, 1.0 mg/kg cyclorphan 
resulted in 100% drug-appropriate responding. In pigeons respond- 
ing under a multiple fixed-interval, fixed-ratio schedule of food 
delivery, cyclorphan produced a complete dose-related reversal of 
the rate-decreasing effects of i0 mg/kg morphine, the maximally 
effective antagonist doses being 1.0-3.2 mg/kg. Higher cyclorphan 
doses (i0 mg/kg) resulted in response rate decreases that were not 
reversed by naloxone (I mg/kg). Thus, cyclorphan has discrimina- 
tive effects that are similar to those of both ethylketazocine and, 
at 20-fold higher doses, cyclazocine. In addition, in morphine- 
treated pigeons, cyclorphan, across the same range of doses that 
produce ethylketazocine-appropriate responding, has discriminative 
effects that are similar to those of naltrexone, an effect that is 
probably related to the antagonist action of the drug. 
Cyclorphan ((-)-3-hydroxy-N-cyclopropylmethyl-morphinan) is a mixed narcotic 
agonist-antagonist which has also been reported to produce psychotomimetic 
activity in man (I). As an analgesic in man, cyclorphan is about 60 times more 
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potent than morphine (i); as an antagonist of the effects of morphine and 
meperidine in animals, cyc]orphan is 3-5 times more potent than nalorphine and 
about 1.5 times less potent than cyclazocine (2), an N-cyc]opropylmethyl deriva- 
tive in the benzomorphan series. In contrast to the well-described analgesic 
and antagonist effects of cyclorphan, the psychotomimetic effects of the drug in 
man are not well documented (see e.g., 1,2,3). 
In unanesthetized dogs and monkeys, cyc]orphan produces behavioral effects 
similar to those produced by cyclazocine. These include: sedation, loss of 
postural reflexes, ataxia, and muscular incoordination (cf. 2,4,5). Like 
cyclazocine, cyclorphan has little or no effect on response to painful stimuli 
in a variety of analgesic tests in rats, dogs, or monkeys (e.g., 2,5). However, 
both are potent analgesics in man (i). Thus, in many respects, the pharma- 
co]ogy of cyclorpban resembles that of cyclazocine, a compound with well- 
documented sedative, dysphoric, and psychotomimetic effects in man (6,7). 
The discriminative effects of cyelorphan in laboratory animals have yet to 
be fully characterized, although in the rhesus monkey, both cyc]orphan and 
cyclazocine have discriminative effects in common with ethy]ketazocine (ethy]- 
ketocyclazocine), the 5-ethyl, 8-keto analogue of cyclazocine (8). Cyclazocine, 
on the other hand, has been more extensively studied in a number of animal 
species (9-]3), and has been shown in rats and pigeons to have discriminative 
effects similar to those of phencyc]idine and ketamine (12-]4). Also, since 
these effects of cyclazocine are relatively resistant to blockade by narcotic 
antagonists (]2-16), it has been suggested that the discriminative effects of 
cyclazocine in these species include an important non-opiate component (12,13), 
and that these effects of the drug may be analogous to the psychotomimetic and 
sedative effects that are known to be produced by cyclazocine and phencyclidine 
in man (6,7,17). 
Since cyclorphan appears to have a complex set of different pharmacological 
actions in man, it was of interest to characterize more completely the dis- 
criminative stimulus effects of the drug. Thus, cyclorphan was administered to 
separate groups of pigeons trained to discriminate cyclazocine, ethy]ketazocine, 
or na]trexone (32 mg/kg) from saline. In addition, cyclorphan was tested in 
pigeons that were chronically administered morphine, I00 mg/kg/day, and trained 
to discriminate 0.] mg/kg na]trexone from saline. In pigeons, cyclazocine has 
diseriminative effects that are similar to those of phencyc]idine (13), but 
which differ from those of morphine (18). In contrast, ethylketazocine 
produces discriminative effects in the pigeon which are similar to those of 
morphine (18). The effects of iligh doses of naltrexone in narcotic-naive 
pigeons represent yet another distinct set of d~scriminative effects in that 
neither ethylketazocine nor cyc]azocine results in na]trexone-appropriate 
responding (]9,20, unpub]ished observations). IIowever, in pigeons that arc 
chronically treated with morphine (i00 mg/kg/day) and trained to discriminate 
low doses of naltrexone from saline, eyclazocine and a number of other 
narcotic antagonists produce naltrexone-appropr[ate responding (2(]), whereas 
ethy]ketazocine, which is devoid of any narcotic antagonist activity (21,22), 
does not produce naltrexone-like discriminative effects (unpublished observa- 
tions). Thus, the discriminative effects of cyclorphan were assessed for their 
similarity to four very different sets of discriminative stimuli. In addition, 
the effects of eyclorphan, administered alone or in combination with morphine 
or naloxone, were studied in pigeons responding under a multiple fixed-interval, 
fixed-ratio schedu]e of food presentation. Cyclazocine has previously been 
shown to be a potent antagonist of the rate-decreasing effects of morphine in 
the pigeon, but the response rate-decreasing effects of cyclazocine Llre not 
reversed by na|oxone (23). 
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Methods 
Subjects. Sixteen White Carneaux pigeons (Veterinary Animal Science Unit, 
Bowman-Gray Medical School, Winston-Salem, NC) were reduced to approximately 
80% of their free-feeding weights. Sufficient mixed grain and Purina Pigeon 
Checkers supplemented the mixed grain earned during experimental sessions to 
maintain these reduced weights. Water and grit were freely available in each 
pigeon's home cage. Results of previous experiments in some of these pigeons 
are described elsewhere (13,24). 
Apparatus. Each experimental chamber contained two translucent response ke 
(2 cm diameter and 5 cm apart), located 25 cm above the floor of the chamber, 
either one of which or both could be transilluminated with red or green 7-W 
lights. Mixed grain from a hopper could be made available through a rectang- 
ular opening located directly below the keys and approximately 10 cm above the 
chamber floor. A white light illuminated the hopper during food delivery. 
Each chamber was ventilated by an exhaust fan, and white noise was present to 
mask extraneous sounds. A more detailed description of the experimental 
chambers has been reported elsewhere (18). Programming, recording, and data 
collection were accomplished with a Texas Instruments 960A computer and cumu- 
lative recorders. 
Drug discrimination studies. Each of 12 pigeons was trained to peck one of 
two red-lit keys by reinforcing successive approximations of the key-peck 
response with 4 set access to mixed grain. Following the acquisition of the 
response, the appropriate key to be pecked to produce grain was determined by 
the injection the pigeon received before the session, i.e., drug (left key) 
or saline (right key). Across sessions, the number of consecutive responses 
required for grain delivery was increased to 20. Responses on the inappro- 
priate key reset the response requirement on the appropriate key. Sessions 
ended after 32 deliveries of mixed grain or 1 hr, whichever occurred first. 
YS 
Training sessions were usually conducted six days per week. Initially, drug 
and saline injections alternated from one session to the next. Drug discrim- 
inations were established with either ethylketazocine (0.32 mg/kg, 4 pigeons), 
cyclazocine (1.8 mg/kg, 2 pigeons), or naltrexone (32 mg/kg, 3 pigeons). In 
addition, a fourth group of 3 pigeons was chronically administered morphine, 
100 mgfkglday, approximately 8 hr before the session, and trained to discrimin- 
ate 0.1 mg/kg naltrexone from saline. In these pigeons, 100 mg/kg morphine was 
administered daily for approximately 1 week before the start of drug discrim- 
ination training and continued to be administered throughout the course of the 
experiment. In the ethylketazocine-trained pigeons, ethylketazocine or saline 
was injected 5 min before the session. In each of the other pigeons, the 
training drug or saline was administered 10 min before the session. 
Training continued in each pigeon until the pigeon met the criteria of 
emitting fewer than 40 responses before the first grain presentation of the 
session and of distributing at least 90% of the total session responses on 
the appropriate key. Each pigeon was required to meet these criteria for five 
consecutive sessions during which saline and drug injections alternated, and 
then on four consecutive sessions prior to which drug or saline was adminis- 
tered in a double alternation sequence (e.g., saline, saline, cyclazocine, 
cyclazocine). 
Once these criteria were met, test sessions were conducted in each bird 
with a range of doses of cyclorphan. Cyclorphan was always injected 10 min 
before the session. Throughout an entire test session, 20 consecutive 
responses on either the drug-appropriate or saline-appropriate key produced 
access to grain; in all other respects, test sessions were identical to 
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training sessions. In general, test sessions alternated during the week with 
training sessions. If during a training session an animal failed to meet the 
training criteria, further testing was postponed until the criteria were met on 
at least two consecutive training sessions. 
Cyclorphan effects on schedule-controlled respondin$. The effects of 
cyclorphan, administered alone or in combination with morphine (i0 mg/kg) or 
naloxone (I mg/kg), were assessed in 4 pigeons responding under a multiple 
fixed-lnterval 5-min (FI 5), flxed-ratio 30-response (FR 30) schedule of food 
delivery (4-sec access to mixed grain). In these studies only a single key was 
lit. When the key was transilluminated by a green light, the first response 
after 5 min resulted in food delivery (FI 5); alternately, 30 responses when 
the key was lit red also resulted in food delivery (FR 30). A l-min limited- 
hold was in effect for both components of the schedule; if a response was not 
emitted within 1 min of the end of the FI or if 30 responses were not emitted 
within 1 min of the onset of the FR component, the schedule advanced into the 
next component. Each session consisted of I0 FI and i0 FR components presented 
in alternation. Sessions were conducted 5 days per week, Monday through Friday 
Drugs or saline were administered immediately before the start of the session, 
no more frequently than twice per week, usually on Tuesdays and Fridays. 
Data analyses. Data for the drug discrimination studies are presented as 
the average number of responses emitted on the drug-appropriate key throughout 
the session, expressed as a percentage of the total session responses. In 
addition, the overall rate of responding on both keys after an injection of 
cyclorphan is presented as a percentage of the rate of responding during the 
saline training sessions that immediately preceded test sessions. 
Results of the studies of drug effects on schedule-controlled responding are 
presented as response rates during the FI and FR components of the schedule, 
expressed as a percentage of the rate of responding in these components during 
sessions prior to which saline was administered. In addition, the effects of 
the drugs on the fixed-interval quarter-life, which provides a measure of tile 
temporal pattern of responding within the interval (see e.g., 25), are also 
expressed as a percentage of the quarter-life values for saline control 
sessions. 
Druss. Cyclorphan hydrochloride (kindly provided by Dr. M. D. Gates, Univ. 
of Rochester, Rochester, ICY and Hoffmann-La Roche Inc., Nutley, NJ), morphine 
sulfate (Mallinckrodt Chemical Works, St. Louis, MO), naloxone hydrochloride, 
and naltrexone hydrochloride (both generously supplied by Endo Laboratories, 
Garden City, NY) were dissolved in 0.9% sterile saline. Ethylketazocine 
methane sulfonate and cyclazocine base (kindly supplied by Dr. W. Michne, 
Sterllng-Winthrop Research Institute, Rensselaer, NY) were dissolved in 
sterile water to which a small amount of lactic acid was added; sodium 
hydroxide was then used to adjust the pH of these solutions to above 4. Drug 
doses refer to the forms described. Injections of all drugs and saline were 
made into the pectoral muscle in a volume of 1 ml/kg. The order of cyclorphan 
doses administered and drug combinations was unsystematic. When drug combina- 
tions were studied, an injection of one drug was made into the pectoral muscle 
on one side of the pigeon, followed immediately by an injection into the 
muscle on the opposite side. 
Results 
Dru$ Discrimination Studies. Each of the 12 pigeons in these experiments 
acquired a drug-sallne discrimination. The average number of sessions to 
reach criterion level performance in each group of pigeons was: 38 for pigeons 
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FIG. 1 
Discriminative stimulus and rate-decreasing effects of cyclorphan. 
Upper panel ordinates: average number of responses emitted on the 
drug-appropriate key, expressed as a percentage of the total session 
responses. Lower panel ordinates: average rate of responding fol- 
lowing drug injection, expressed as a percentage of the rate of 
responding on saline training sessions. Response rates following 
saline injections ranged in individual pigeons from 1.32 to 3.89 
responses/sec. Abscissae: cyclorphan dose, mg/kg. Each point is 
the average of 4 (ethylketazocine-trained), 2 (cyclazocine-trained), 
3 (naltrexone-trained, narcotic-naive), or 3 (naltrexone-trained, 
morphine-treated) pigeons, except as noted below. Training condi- 
tions are indicated by different symbols in the key to the figure. 
Points at D in the lower panels indicate the rate of responding 
following the administration of the training drugs. Refer to the 
text for additional information on the training conditions. *Only 
3 ethylketazocine-trained pigeons received i0 mg/kg cyc]orphan. 
Following this dose of cyclorphan, only 1 of these pigeons responded 
during the one hr session, and this pigeon responded exclusively on 
the saline-appropriate key. One naltrexone-trained, narcotic-naive 
pigeon did not respond during the session following i0 mg/kg 
cyclorphan. The dashed lines at 90% in the upper panels indicate 
the minimum level of drug-appropriate responding that the training 
drugs were required to produce before test sessions were conducted 
with cyclorphan. 
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trained to discriminate ethylketazocine from saline, 36 for pigeons trained to 
discriminate cyclazocine from saline, 49 for narcotic-naive pigeons trained to 
discriminate 32 mg/kg naltrexone from saline, and 33 for morphine-treated 
pigeons trained to discriminate 0.i mg/kg naltrexone from saline. 
Cyclorphan produced varying degrees of drug-appropriate responding that 
depended both on the training conditions and on the dose of cyclorphan admin- 
istered (Fig. I, upper panels). In pigeons trained to discriminate ethyl- 
ketazocine from saline, cyclorphan produced a dose-related increase in the 
number of responses that were made on the ethylketazocine-appropriate key, the 
maximum effect (83%) occurring at 0.3 mg/kg cyclorphan. This dose of cyclor- 
phan produced at least 90% ethylketazocine-appropriate responding in 3 out of 
4 pigeons and only 35% in the fourth. Higher cyclorphan doses did not increase 
the average percentage of drug-appropriate responses. In the one pigeon that 
responded only 35% on the drug-appropriate key after the administration of 0.3 
mg/kg cyclorphan, as the dose of cyclorphan increased beyond 1 mg/kg, drug- 
appropriate responding decreased. 
In pigeons trained to discriminate cyclazocine from saline, a dose of 
cyclorphan (I mg/kg) that produced 80% ethyl ketazocine-appropriate responding, 
produced only saline-appropriate responding (Fig. i). As the dose of cyclor- 
phan increased, cyc]azocine-appropriate responding increased to above 90% at 
5.6-10.0 mg/kg cyclorphan. 
Cyclorphan produced the least amount of drug-appropriate responding in 
narcotic-naive pigeons trained to discriminate 32 mg/kg naltrexone from saline, 
resulting in an average maximum effect of less than 50% drug-appropriate 
responding at 3.2 mg/kg cyclorphan (Fig. ]). In contrast, in pigeons that were 
chronically administered i00 mg/kg/day morphine and trained to discriminate 
0.] mg/kg naltrexone, cyclorphan produced a dose-related increase in the per- 
centage of total responses that were emitted on the naltrexone-appropriate key, 
with 1.0 mg/kg cyclorphan producing 100% drug-appropriate responding in each 
pigeon. These effects of cyclorphan occurred across a range of doses that also 
produced ethylketazocine-appropriate responding. 
~en tested at sufficiently high doses, cyclorphan produced similar dose- 
related effects on the rate of responding in each group of pigeons (Fig. i, 
lower panels). A dose of i0 mg/kg cyclorphan generally suppressed responding 
in each pigeon tested, and marked ataxia and loss of postural reflexes were 
noted. Two ethylketazocine-trained pigeons and ] naltrexone-trained pigeon 
did not respond at all following the administration of this dose of cyclorphan. 
Cyc]orphan effects on schedule-controlled responding. The effects of 
cyclorphan, administered alone or in combination with i0 mg/kg morphine or I 
mg/kg naloxone, on performances maintained under the multiple schedule of food 
delivery are sholml in Fig. 2. When administered alone (open circles), 1-3.2 
mg/kg cyclorphan had little or no effect on FR or FI response rates or on FI 
quarter-life values. However, the highest dose of cyclorphan (i0 mg/kg) de- 
creased responding in both components of the schedule and decreased the FI 
quarter-life value to approximately 60% of control. The co-administration of 
1 mg/kg naloxone (open triangles), a dose of naloxone sufficient to reverse 
completely the effects of i0 mg/kg morphine on schedule-controlled responding 
in pigeons (26,27), did not block the effects of I0 mg/kg eye]orphan either on 
FR or FI rates of responding or on FI quarter-life. 
Morphine (i0 mg/kg), when administered alone (Fig. 2, closed circles at "M"), 
suppressed responding in both components of the schedule to less than 10% of 
the control rate and decreased the FI quarter-life by 20%. When administered 
with morphine, increasing doses of cyclorphan (closed circles) resulted in a 
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FIG. 2 
Effects of cyclorphan, administered alone (open circles) or in com- 
bination with i0 mg/kg morphine (closed circles) or 1.0 mg/kg 
naloxone (open triangles), on responding maintained under a multiple 
FI, FR schedule of food presentation. Ordinates: percent of control. 
Control values were calculated from sessions in which saline was ad- 
ministered. Average response rates following saline injections were 
0.91 and 2.87 responses/sec during the FI and FR components, respec- 
tively. The FI quarter-life value for these sessions was 174 sec 
(58% of the 5-min interval). Abscissae: cyclorphan dose, mg/kg. 
Each point represents the mean of a single observation in each of 4 
pigeons. Lines through the points indicate + 1 S.E.M. Points at M 
represent the effects of I0 mg/kg morphine administered alone. 
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dose-related reversal of the effects of morphine on all measures of schedule- 
controlled behavior. The highest dose of cyclorphan (i0 mg/kg) was consider- 
ably less effective as an antagonist of morphine on a]l aspects of performance 
than were appropriate lower doses of cyclorphan. 
Discussion 
Cyclorphan produced discriminative effects that varied as a function of dose 
and training condition. In pigeons trained to discriminate ethylketazocine 
from saline, cyclorphan produced greater than 90% drug-appropriate responding 
in 3 out of 4 pigeons and a maximum average response of 83% at 0.3 mg/kg, in- 
dicating considerable ethylketazocine-like activity. Although ethylketazocine 
has usually been shown to have discriminative effects that differ from those of 
morphine in many species (8,11,28), the discriminative effects of morphine and 
ethylketazocine are virtua]ly indistinguishable in the pigeon (18,24). More- 
over, in pigeons trained to discriminate morphine from saline, cyclorphan pro- 
duces effects (unpublished observations) almost identical to those observed in 
the present study in pigeons trained to discriminate ethylketazocine from 
saline (Fig. i). Thus, appropriate doses of cyclorphan appear to produce dis- 
criminative effects similar to those of ethy]ketazocine or morphine in ti~e 
pigeon. 
The inability of cyclorphan to produce greater than 90% ethylketazocine- 
appropriate responding in all pigeons tested suggests that cyclorphan may have 
effects, particularly at higher doses, that differ from those of ethyl- 
ketazocine. In pigeons trained to discriminate cyclazocine from saline, 
cyclorphan produced greater than 90% cyclazocine-appropriate responding at 5.6- 
I0 mg/kg, doses of the drug 20-30 times higher than the lowest doses needed to 
produce ethylketazocine-appropriate responding. While ethylketazocine has 
discriminative effects in pigeons that are similar to those of morphine, the 
discriminative effects of cyclazocine differ considerably from those of either 
morphine or ethylketazocine (18,24), but are similar to those of the non- 
narcotics phencyclidine and ketamine (13). In addition, the discriminative 
effects of cyclazocine and cyclazocine-like compounds, including phencyclidine 
and ketamine, are not well antagonized, if at all, by naloxone or naltrexone in 
rats (12,14) or pigeons (unpublished observations), indicating that certain of 
the effects of these drugs are mediated through non-narcotic mechanisms. Thus, 
at relatively high doses, cyclorphan appears to have non-narcotic, cyclazocine- 
like discriminative effects. ]'he non-narcotic discriminative effects of 
cyclorphan, cyclazocine and phencyclidine may reflect interactions with the 
proposed "phencyclidine" receptor (29,30), since the relative potencies of 
these compounds in producing these discriminative effects are in close agree- 
ment with their relative potencies in displacing [3H] PCP binding to rat brain 
homogenates (cf. Fig. i; 13,31). That the high dose effects of cyclorphan are 
non-narcotic in nature is also supported by the finding that the effects of 10 
mg/kg cyclorphan on schedule-controlled responding were not reversed by 
naloxone (Fig. 2). 
The intermediate level of responding produced by cyclorphan in ethylketazo- 
cine-tralned pigeons, although limited to 1 out of 4 subjects in the present 
experiment, is not an uncommon finding in studies of narcotic drug discrimin- 
ation (see 18,32-35). For example, a number of narcotic analgesics with 
activity as morphine antagonists (e.g., cyclazocine, nalorphine, levallorphan, 
nalbuphine) produce average maximum effects less than that produced by the 
training drug, morphine (34,35). Interpretation of intermediate levels of 
drug-appropriate responding is difficult, but are often ascribed to being a 
consequence of the test compound being somewhat similar to the training drug. 
In man, many narcotic mixed agonist-antagonists, while having morphine-like 
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subjective effects at low doses, tend to have predominantly non-morphine-like 
effects including sedation and psychotomimetic effects at higher doses (7). 
These additional non-morphine-like effects of these compounds may contribute 
to the intermediate or biphasic nature of dose-effect curves obtained with 
these drugs in animals trained to discriminate morphine-like compounds. Results 
of the present experiment suggest that at low doses cyclorphan has morphine-like 
discriminative effects, and that the drug's non-morphine-like actions can be 
accounted for by the drug's cyclazocine- or phencyclidine-like activity at 
higher doses. Indeed, intermediate levels of drug-appropriate responding 
produced by cyclorphan are completely reversed by naltrexone in pigeons trained 
to discriminate morphine from saline (unpublished observations) but are en- 
hanced by naltrexone in pigeons trained to discriminate ketamine from saline 
(36), indicating the existence of at least two components of activity for 
cyclorphan. 
In rats, the discriminative effects of cyclazocine appear to be similarly 
bimodal. In rats trained to discriminate morphine or fentanyl from vehicle, 
cyclazocine produces maximum drug-appropriate responding at a dose of approxi- 
mately 0.3 mg/kg (32,33). Higher doses of the drug produce less morphine- or 
fentanyl-appropriate responses. These higher doses of cyclazocine in rats have 
non-morphine-like discriminative effects that are similar to those of 
phencyclidine (14). 
In addition to having both ethylketazocine- and cyclazocine-like discrimina- 
tive effects, cyclorphan was shown to have discriminative effects similar to 
those of the narcotic antagonist naltrexone in pigeons chronically administered 
morphine, but not in morphine-naive pigeons. This effect is similar to that 
produced by a number of other narcotic antagonists including cyclazocine, 
nalorphine, and diprenorphine, that result in na]trexone-appropriate responding 
in morphine-treated pigeons but not in narcotic-naive pigeons (19,20). Com- 
pounds that are not antagonists of morphine (e.g., amphetamine, physostigmine, 
bicuculline) do not produce naltrexone-appropriate responding in chronically 
morphinized pigeons (37), suggesting that the discriminative effects of cyc- 
lorphan in these pigeons are related to the antagonist action of the drug, and 
it has been proposed that the discriminative effects of narcotic antagonists 
in morphine-treated animals represent stimuli associated with antagonist- 
precipitated abstinence (38,39). That the effects of cyclorphan in morphine- 
treated pigeons are intimately related to the drug's antagonist activity is 
supported by results of cyclorphan's antagonism of the acute effects of 
morphine. A dose of cyclorphan (i.0 mg/kg) that produced 100% naltrexone- 
appropriate responding in pigeons chronically administered morphine (Fig. i), 
completely blocked the effects of morphine on schedule-controlled responding 
(Fig. 2). Interestingly, these antagonist effects of cyclorphan occur within 
a range of doses of the drug that also produce ethylketazocine-]ike agonist 
activity. 
Thus, the multiple actions of cyclorphan result in at least 3 distinct 
classes of discriminative stimuli, the predominant stimulus action being deter- 
mined by dose and narcotic history. At low doses, cyclorphan produces 
ethylketazocine-like discriminative effects, and at higher doses, non-narcotic 
cyclazocine-]ike activity, the latter effect, perhaps, being analogous to the 
psychotomimetic effects that are produced by cyclorphan in man. At doses that 
produce ethylketazocine-appropriate responding, cyclorphan also produces, in 
pigeons chronically administered morphine, discriminative effects that are 
naltrexone-like, an effect that is related to the antagonist action of the drug 
and which may represent stimuli associated with antagonist-precipitated 
withdrawal. 
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